Bonifaz Alexandro, Fierro Leonel, Saúl Amado, Ponce Rosa María
Dermatology Service & Mycology Department, Hospital General de México OD, Sánchez Azcona 317 int 202, Col del Valle, 03020 Mexito City, Mexico.
Eur J Dermatol. 2008 Jan-Feb;18(1):61-4. doi: 10.1684/ejd.2008.0312. Epub 2007 Dec 18.
Sporotrichosis is a subcutaneous and exceptionally deep mycosis caused by a dimorphic fungus, Sporothrix schenckii. Itraconazole is a triazole derivative leading to good results in the treatment of sporotrichosis. Patients with cutaneous sporotrichosis proven with mycological tests (direct examination and culture) were enrolled. All patients underwent laboratory tests (at baseline and on a monthly basis) and received oral itraconazole 400 mg/day for one week with a 3-week break (pulses); thereafter the drug was administered as pulses until clinical and mycological cure was achieved. Five patients with sporotrichosis were enrolled, 4 with cutaneous lymphangitic form and one with fixed cutaneous form. Clinical and mycological cure was achieved in 4/5 cases (80%), with a mean number of pulses of 3.5. No patient had side effects and no laboratory test abnormalities occurred. Intermittent or pulsed itraconazole was effective in treating cutaneous sporotrichosis. It may be considered as a new treatment choice that entails an important reduction in total medication use.
孢子丝菌病是一种由双相真菌申克孢子丝菌引起的皮下及极深部真菌病。伊曲康唑是一种三唑衍生物，在治疗孢子丝菌病方面取得了良好效果。纳入经真菌学检测（直接检查和培养）证实的皮肤孢子丝菌病患者。所有患者均接受实验室检查（基线时和每月一次），并接受口服伊曲康唑400mg/天，持续一周，休息3周（脉冲疗法）；此后，该药物以脉冲疗法给药，直至实现临床和真菌学治愈。纳入了5例孢子丝菌病患者，4例为皮肤淋巴管型，1例为固定皮肤型。4/5例（80%）实现了临床和真菌学治愈，平均脉冲次数为3.5次。没有患者出现副作用，也未发生实验室检查异常。间歇性或脉冲式伊曲康唑在治疗皮肤孢子丝菌病方面有效。它可被视为一种新的治疗选择，能显著减少总用药量。
